Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Barton

Showing results (181-190 of 297) with videos related to

Pageof 30
Sort By:
Annals of the Rheumatic Diseases|September 12, 2023
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritisChuan Fu Yap, Nisha Nair, Annick de Vries, et al.
Nature Reviews. Disease Primers|February 9, 2018
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Anne Barton, et al.
Genome Medicine|September 5, 2018
Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twinsAmy P Webster, Darren Plant, Simone Ecker, et al.
Seminars in Arthritis and Rheumatism|November 13, 2018
Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meetingSonya Abraham, Anne Barton, Lihi Eder, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association studyGisela Orozco, Sebastien Viatte, John Bowes, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysisSamantha Louise Smith, Sheree Alexander, Nisha Nair, et al.
Oncotarget|December 10, 2017
<i>KIF3A</i> and <i>IL-4</i> are disease-specific biomarkers for psoriatic arthritis susceptibilityRaffaella Cascella, Claudia Strafella, Michele Ragazzo, et al.
Rheumatology (Oxford, England)|May 13, 2025
Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritisStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Pageof 30

Showing results (181-190 of 297) with videos related to

Sort By:
Pageof 30
Annals of the Rheumatic Diseases|September 12, 2023
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritisChuan Fu Yap, Nisha Nair, Annick de Vries, et al.
Nature Reviews. Disease Primers|February 9, 2018
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Anne Barton, et al.
Genome Medicine|September 5, 2018
Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twinsAmy P Webster, Darren Plant, Simone Ecker, et al.
Seminars in Arthritis and Rheumatism|November 13, 2018
Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meetingSonya Abraham, Anne Barton, Lihi Eder, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2014
Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association studyGisela Orozco, Sebastien Viatte, John Bowes, et al.
Rheumatology Advances in Practice|January 5, 2026
Patterns of steroid use in patients with established rheumatoid arthritis commencing treatment with biologic or targeted synthetic DMARDsMichael Stadler, Shae Bindra, Annie Cheung, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysisSamantha Louise Smith, Sheree Alexander, Nisha Nair, et al.
Oncotarget|December 10, 2017
<i>KIF3A</i> and <i>IL-4</i> are disease-specific biomarkers for psoriatic arthritis susceptibilityRaffaella Cascella, Claudia Strafella, Michele Ragazzo, et al.
Rheumatology (Oxford, England)|May 13, 2025
Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritisStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Pageof 30